Abstract
Imaging has long been indispensable in clinical practice. Increasingly, in vivo imaging of small laboratory animals (i.e., mice and rats) has emerged as a critical component of preclinical biomedical research as well (Beckman et al. 2007; Cherry 2006; Gross and Piwnica-Worms 2006; Pomper 2005). Small-animal imaging provides a noninvasive means of assaying biological structure and function in vivo, yielding quantitative, spatially and temporally indexed information on normal and diseased tissues such as tumors. Importantly, because of its noninvasive nature, imaging allows serial (i.e., longitudinal) assay of rodent models of human cancer and cardiovascular, neurological, and other diseases over the entire natural history of the disease process, from inception to progression, and monitoring of the effectiveness of treatment or other interventions (with each animal serving as its own control and thereby reducing biological variability). This also serves to minimize the number of experimental animals required for a particular study. With the ongoing development of genetically engineered (i.e., transgenic and knock out) rodent models of cancer and other critical diseases (Malakoff 2000), such models are increasingly more realistic in recapitulating the natural history and clinical sequelae of the corresponding human disease and the ability to track these disease models long-term is therefore invaluable. Importantly, in contrast to cell or tissue culture-based experiments, studies in intact animals incorporate all of the interacting physiological factors – neuronal, hormonal, nutritional, immunological, etc. – present in the complex in vivo milieu. Intact whole-animal models also facilitate investigation of systemic aspects of disease such as cancer metastasis, which are difficult or impossible to replicate in ex vivo systems. Further, because many of the same imaging modalities – magnetic resonance imaging and spectroscopic imaging (MRI and MRSI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), transmission computed tomography (CT), and ultrasound (US) – used in the clinic are also used in the laboratory setting, the findings of small-animal imaging are readily translatable to patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Fluorescence imaging is being pursued clinically in intraoperative, laparoscopic, and endoscopic settings, where there is no overlying tissue.
References
Beckman N, Kneuer R, Gremlcih HU et al (2007) In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed 20:154–185
Cherry S (2006) In-vivo whole-body imaging of the laboratory mouse. In: Fox J, Barthold S, Davisson M, Newcomer C, Quimby F, Smith A (eds) The mouse in biomedical research, vol 3 (Normative biology, husbandry, and models), 2nd edn. Elsevier Academic, San Diego
Cho HJ, Ackerstaff E, Carlin S et al (2009) Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic MRI and PET studies of a preclinical tumor model of tumor hypoxia. Neoplasia 11:247–259
Contag PR, Olomu IN, Stevenson DK (1998) Bioluminescent indicators in living mammals. Nat Med 4:245–247
Gross S, Piwnica-Worms D (2006) Molecular imaging strategies for drug discovery and development. Curr Opinion Chem Biol 10:334–342
Hoffmann U, Brix G, Knopp MV et al (1995) Pharmokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33:506–514
Lindner J (2004) Microbubbles in medical imaging: current applications and future directions. Nature Rev Drug Discov 3:527–532
Malakoff D (2000) Suppliers: the rise of the mouse, biomedicine’s model mammal. Science 288:248–253
Ntziachristos V, Tung CH, Bremer C et al (2002) Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 8:757–760
Ntziachristos V, Ripoli J, Wang LV et al (2005) Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 23:313–320
Pichler BJ, Wehrl HF, Kolb A et al (2008) Positron emission tomography/magnetic resonance imaging: the next generation of multi-modality imaging. Semin Nucl Med 38:199–208
Pomper MG (2001) Molecular imaging: an overview. Acad Radiol 8:1141–1153
Pomper MG (2005) Translational molecular imaging for cancer. Cancer Imaging 5:S16–S26
Rowland DJ, Cherry SR (2008) Small-animal nuclear medicine: Instrumentation and related considerationsin pre-clinical research. Semin Nucl Med 38:208–222
Serganova I, Mayer-Kukuck HH et al (2008) Molecular imaging: reporter gene imaging. In: Semmler W, Schwaiger M (eds) Molecular imaging II. Handbook of experimental pathology 185/II. Springer, Berlin
Smith-Jones PM, Solit DB, Akhurst T et al (2004) The pharmacodynamics of HER2 degradation in response to HSP90 inhibitors can be imaged in animals with 68Ga labeled F(ab′)2 fragments of Herceptin. Nat Biotechnol 22:701–706
Wisner ER, Weichert JP, Longino M et al (2002) A surface-modified chylomicron remnant-like emulsion for percutaneous computed tomography lymphography: synthesis and preliminary imaging findings. Invest Radiol 37:232–239
Zanzonico P (2008) Multimodality image registration and fusion. In: Dhawan AP, Huang HK, Kim DS (eds) Principles and advanced methods in medical imaging and image analysis. World Scientific, Singapore
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zanzonico, P. (2011). Noninvasive Imaging for Supporting Basic Research. In: Kiessling, F., Pichler, B. (eds) Small Animal Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12945-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-12945-2_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12944-5
Online ISBN: 978-3-642-12945-2
eBook Packages: MedicineMedicine (R0)